Achievement and maintenance of complete remission in a patient with acute myelogenous leukemia after weekly administration of interleukin-2

Haematologica. Jul-Aug 1996;81(4):346-8.


Several groups have used high doses of interleukin-2 (IL-2), achieving a significant rate of responses in patients with acute myelogenous leukemia (AML). These results have mainly been observed in AML patients with limited disease (bone marrow blasts < 25%), but this therapy is associated with significant toxicity which is dose-related. In this report we describe a patient with AML in whom conventional chemotherapy had achieved partial remission. This patient received subcutaneously intermediate doses of IL-2 (12 x 10(6)/m2/week) and achieved complete remission which was maintained for eleven months. The side effects of IL-2 were mild. The results of this report document the antileukemic effect of IL-2 in AML with limited disease as well as the efficacy of subcutaneous maintenance treatment for prolonged periods.

Publication types

  • Case Reports

MeSH terms

  • Humans
  • Injections, Subcutaneous
  • Interleukin-2 / administration & dosage*
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Middle Aged
  • Recombinant Proteins / administration & dosage


  • Interleukin-2
  • Recombinant Proteins